Offsetting of aberrations associated with seizure proneness in rat hippocampus area CA1 by theta pulse stimulation-induced activity pattern.
Epileptiform activity induces long term aberrations in hippocampal network functions. This study was conducted in pentylenetetrazol (PTZ) -kindled rats to examine offsetting of aberrations associated with seizure proneness in hippocampus area CA1 by theta pulse stimulation (TPS: 5 Hz trains for 3 min) -induced activity pattern. In hippocampal slices from both control and kindled rats, the field excitatory postsynaptic potentials (fEPSP) and population spikes (PS) were simultaneously recorded through electrodes in the apical dendrites and stratum pyramidale, respectively. The following changes in kindled vs. control slices were observed. The fEPSP needed to be greater to produce the PS recorded in the cell body layer. The fEPSP was reduced by paired stimuli whereas the PS amplitude was increased. TPS selectively depressed the PS in a lasting fashion, and shifted the fEPSP slope and the PS amplitude relation toward what was observed in controls. Both the fEPSP and PS were increased by paired stimuli at 60 min after TPS application. The lasting depressive effect of TPS on the PS amplitude was converted into facilitation by adenosine A1 receptor antagonist 8-cyclopentyl-1, 3-dipropylxanthine (CPX). Potentiation of the PS amplitude by TPS in the presence of CPX was blocked by an N-methyl-d-aspartate receptor antagonist AP5. We hypothesize that the extracellular adenosine spillover, acting through adenosine A1 receptors, during TPS-induced activity pattern could trigger a homeostatic process for correcting network imbalances caused by epileptiform activity.
Salmani
M E
ME
Department of Physiology, School of Medical Sciences, Tarbiat Modares University, PO Box 14115-111, Tehran, Iran.
Mirnajafizadeh
J
J
Fathollahi
Y
Y
D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000241:Adenosine / Q000378:metabolism / Q000502:physiology; D058916:Adenosine A1 Receptor Antagonists; D000818:Animals; D003292:Convulsants / Q000494:pharmacology; D003627:Data Interpretation, Statistical; D004558:Electric Stimulation; D004567:Electrodes, Implanted; D004569:Electroencephalography; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects; D006624:Hippocampus / Q000503:physiopathology*; D066298:In Vitro Techniques; D007696:Kindling, Neurologic / Q000502:physiology; D008297:Male; D009415:Nerve Net / Q000503:physiopathology; D010433:Pentylenetetrazole / Q000494:pharmacology; D017966:Pyramidal Cells / Q000187:drug effects / Q000502:physiology; D051381:Rats; D043682:Receptor, Adenosine A1 / Q000502:physiology; D012640:Seizures / Q000503:physiopathology*; D013569:Synapses / Q000187:drug effects
D058916:Adenosine A1 Receptor Antagonists; D003292:Convulsants; D018691:Excitatory Amino Acid Antagonists; D043682:Receptor, Adenosine A1; D015763:2-Amino-5-phosphonovalerate; D000241:Adenosine; D010433:Pentylenetetrazole